O tratamento com omalizumabe para asma al\u00e9rgica grave n\u00e3o controlada apesar do uso de corticoide inalat\u00f3rios (CI) associado a um beta2-agonista de longa a\u00e7\u00e3o (LABA) ser\u00e1 implementado pelo Sistema \u00danico de Sa\u00fade (SUS).<\/p>\n
Em 18\/09\/19, a SBPT enviou parecer contr\u00e1rio \u00e0 recomenda\u00e7\u00e3o da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (CONITEC) e, portanto, favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do omalizumabe.<\/p>\n
O parecer da Sociedade tem base em artigos cient\u00edficos que indicam redu\u00e7\u00e3o das exacerba\u00e7\u00f5es, melhora do controle da asma e da qualidade de vida\u00b9.<\/p>\n
Al\u00e9m disso, o omalizumabe pode evitar que o paciente seja submetido \u00e0 terapia com corticoesteroides sist\u00eamicos e exposto aos seus efeitos adversos, que incluem osteoporose, catara e glaucoma, obesidade, hipertens\u00e3o e diabetes.<\/p>\n
No formul\u00e1rio de opini\u00e3o enviado \u00e0 CONITEC, a Comiss\u00e3o da Asma da SBPT enfatiza que a orienta\u00e7\u00e3o sobre a t\u00e9cnica de uso dos dispositivos inalat\u00f3rios, a necessidade de ades\u00e3o ao tratamento e de controle de comorbidades s\u00e3o obrigat\u00f3rios antes de mudar a etapa do tratamento e adicionar uma terceira medica\u00e7\u00e3o.<\/p>\n
Devido ao alto custo do tratamento, a sele\u00e7\u00e3o do perfil de paciente beneficiado deve ser criteriosa. Estima-se que apenas 3,7% dos pacientes com asma grave s\u00e3o avaliados para o uso do omalizumabe como terapia adicional para o controle de sintomas.<\/p>\n
\u00b9Refer\u00eancias Bibliogr\u00e1ficas<\/p>\n
1. Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012. Mar;49(2):144-52.
\n2. Rubin AS1, Souza-Machado A, Andradre-Lima M, Ferreira F, et al, ; QUALITX Study Investigators. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).. J Asthma. 2012 Apr;49(3):288-93.
\n3. Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, Leo J, Peckitt C, Maykut R, Peachey G.
\nPersistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011 May;66(5):671-8
\n4. Hanania NA1, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 May 3;154(9):573-82.
\n5. Ohta K1, Miyamoto T, Amagasaki T, Yamamoto M; 1304 Study Group. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology. 2009 Nov;14(8):1156-65.
\n6. Niven R1, Chung KF, Panahloo Z, Blogg M, Ayre G. Respir Med. 2008 Oct;102(10):1371-8.Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
\n7. Humbert M1, Beasley R, Ayres J, Slavin R, H\u00e9bert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005 Mar;60(3):309-16.
\n8. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H.Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004 Jul;59(7):701-8.
\n9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding
\nnecessary? Control Clin Trials 1996;17:1\u201312.
\n10. Norman G1, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol. Assess. 2013 Nov;17(52):1-342.
\n11. Shea BJ1, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res. Methodol. 2007 Feb 15;7:10.
\n12. Classifica\u00e7\u00e3o peri\u00f3dicos. https:\/\/sucupira.capes.gov.br\/sucupira\/public\/consultas\/coleta\/veiculoPublicacaoQualis\/listaConsultaGeralPeriodicos.jsf. Acesso em 16\/09\/2019
\n13. Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S34-48.
\n14. GINA. Global Strategy for Asthma Management and Prevention Difficult-to-treat& Severe asthma 2019
\n15. Carvalho \u2013Pinto R.M, Agondi R.C, Giavina-Bianchi P, Cukier A, Stelmach R Omalizumabe em pacientes com asma grave n\u00e3o controlada: crit\u00e9rios de elegibilidade bem definidos para promover o controle da asma. J. bras. pneumol.vol.43 no.6 S\u00e3o Paulo Nov.\/Dec. 2017.<\/p>\n","protected":false},"excerpt":{"rendered":"O tratamento com omalizumabe para asma al\u00e9rgica grave n\u00e3o controlada apesar do uso de corticoide inalat\u00f3rios (CI) associado a um beta2-agonista de longa a\u00e7\u00e3o (LABA) ser\u00e1 implementado pelo Sistema \u00danico de Sa\u00fade (SUS). Em 18\/09\/19, a SBPT enviou parecer contr\u00e1rio \u00e0 recomenda\u00e7\u00e3o da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (CONITEC) [\u2026]","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ngg_post_thumbnail":0,"footnotes":""},"categories":[68],"tags":[102,150,115,755,679,111],"class_list":["post-14488","post","type-post","status-publish","format-standard","hentry","category-noticias","tag-asma","tag-asma-grave","tag-conitec","tag-laba","tag-omalizumabe","tag-sus"],"acf":[],"yoast_head":"\n